OBJECTIVES: To examine the associations between current use, duration, and potency of angiotensin-converting enzyme (ACE) inhibitors and incident frailty in women aged 65 and older who were not frail at baseline. DESIGN: Data were from the Women's Health Initiative Observational Study (WHI-OS), a prospective study conducted at 40 U.S. clinical centers. PARTICIPANTS: Women aged 65 to 79 at baseline who were not frail (N=27,378). MEASUREMENTS: Current ACE inhibitor use was ascertained through direct inspection of medicine containers at baseline. Components of frailty were self-reported low physical function or impaired walking, exhaustion, low physical activity, and unintended weight. Frailty was ascertained through self-reported and physical measurements data at baseline and 3-year clinic contacts. RESULTS: By the 3-year follow-up, 3,950 (14.4%) women had developed frailty. Current ACE inhibitor use had no association with incident frailty (multivariate adjusted odds ratio=0.96, 95% confidence interval=0.82-1.13). Duration and potency of ACE inhibitor use were also not significantly associated with incident frailty. A similar pattern of results was observed when incident cardiovascular disease events were studied as a separate outcome or when the sample was restricted to subjects with hypertension. CONCLUSION: Overall, incidence of frailty was similar in current ACE inhibitor users and nonusers.
OBJECTIVES: To examine the associations between current use, duration, and potency of angiotensin-converting enzyme (ACE) inhibitors and incident frailty in women aged 65 and older who were not frail at baseline. DESIGN: Data were from the Women's Health Initiative Observational Study (WHI-OS), a prospective study conducted at 40 U.S. clinical centers. PARTICIPANTS: Women aged 65 to 79 at baseline who were not frail (N=27,378). MEASUREMENTS: Current ACE inhibitor use was ascertained through direct inspection of medicine containers at baseline. Components of frailty were self-reported low physical function or impaired walking, exhaustion, low physical activity, and unintended weight. Frailty was ascertained through self-reported and physical measurements data at baseline and 3-year clinic contacts. RESULTS: By the 3-year follow-up, 3,950 (14.4%) women had developed frailty. Current ACE inhibitor use had no association with incident frailty (multivariate adjusted odds ratio=0.96, 95% confidence interval=0.82-1.13). Duration and potency of ACE inhibitor use were also not significantly associated with incident frailty. A similar pattern of results was observed when incident cardiovascular disease events were studied as a separate outcome or when the sample was restricted to subjects with hypertension. CONCLUSION: Overall, incidence of frailty was similar in current ACE inhibitor users and nonusers.
Authors: Howard Bergman; Luigi Ferrucci; Jack Guralnik; David B Hogan; Silvia Hummel; Sathya Karunananthan; Christina Wolfson Journal: J Gerontol A Biol Sci Med Sci Date: 2007-07 Impact factor: 6.053
Authors: Gina D Schellenbaum; Nicholas L Smith; Susan R Heckbert; Thomas Lumley; Thomas D Rea; Curt D Furberg; Mary F Lyles; Bruce M Psaty Journal: J Am Geriatr Soc Date: 2005-11 Impact factor: 5.562
Authors: Marcello Maggio; Gian Paolo Ceda; Fulvio Lauretani; Marco Pahor; Stefania Bandinelli; Samer S Najjar; Shari M Ling; Shehzad Basaria; Carmelinda Ruggiero; Giorgio Valenti; Luigi Ferrucci Journal: Am J Cardiol Date: 2006-03-31 Impact factor: 2.778
Authors: Y-J Cao; D E Mager; E M Simonsick; S N Hilmer; S M Ling; B G Windham; V Crentsil; S Yasar; L P Fried; D R Abernethy Journal: Clin Pharmacol Ther Date: 2007-08-22 Impact factor: 6.875
Authors: Joshua I Barzilay; Caroline Blaum; Tisha Moore; Qian Li Xue; Calvin H Hirsch; Jeremy D Walston; Linda P Fried Journal: Arch Intern Med Date: 2007-04-09
Authors: Mariann M Gabrawy; Sarah Campbell; Mary Anna Carbone; Tatiana V Morozova; Gunjan H Arya; Lavanya B Turlapati; Jeremy D Walston; Michelle Starz-Gaiano; Logan Everett; Trudy F C Mackay; Jeff Leips; Peter M Abadir Journal: J Gerontol A Biol Sci Med Sci Date: 2019-11-13 Impact factor: 6.053
Authors: Shelly L Gray; Robert M Boudreau; Anne B Newman; Stephanie A Studenski; Ronald I Shorr; Douglas C Bauer; Eleanor M Simonsick; Joseph T Hanlon Journal: J Am Geriatr Soc Date: 2011-11-04 Impact factor: 5.562
Authors: Shelly L Gray; Aaron K Aragaki; Michael J LaMonte; Barbara B Cochrane; Charles Kooperberg; Jennifer G Robinson; Nancy F Woods; Andrea Z LaCroix Journal: J Am Geriatr Soc Date: 2012-11-23 Impact factor: 5.562